CNS Pharmaceuticals Files Q1 2025 10-Q

Ticker: CNSP · Form: 10-Q · Filed: 2025-05-15T00:00:00.000Z

Sentiment: neutral

Topics: 10-Q, financials, pharmaceuticals

TL;DR

**CNS Pharmaceuticals Q1 2025 10-Q filed. Financials and operations update.**

AI Summary

CNS Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business operations. Specific financial figures for the quarter and comparative periods are detailed within the filing.

Why It Matters

This filing provides investors with the latest financial health and operational status of CNS Pharmaceuticals, Inc., crucial for understanding its current performance and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, CNS Pharmaceuticals faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
2025-05-15 — Filing Date (The date the 10-Q was officially submitted to the SEC.)

Key Players & Entities

CNS Pharmaceuticals, Inc. (company) — Filer of the 10-Q
20250331 (date) — End of the reporting period
20250515 (date) — Filing date
HOUSTON (location) — Company headquarters city
NV (location) — State of incorporation

FAQ

What is the reporting period for this 10-Q filing?

The reporting period for this 10-Q filing is for the quarter ended March 31, 2025.

When was this 10-Q filed with the SEC?

This 10-Q was filed on May 15, 2025.

What is the company's name and Central Index Key (CIK)?

The company's name is CNS Pharmaceuticals, Inc., and its Central Index Key is 0001729427.

In which state was CNS Pharmaceuticals, Inc. incorporated?

CNS Pharmaceuticals, Inc. was incorporated in Nevada (NV).

What is the business address of CNS Pharmaceuticals, Inc.?

The business address is 2100 WEST LOOP SOUTH, SUITE 900, HOUSTON, TX 77027.

From the Filing

0001683168-25-003733.txt : 20250515 0001683168-25-003733.hdr.sgml : 20250515 20250515170020 ACCESSION NUMBER: 0001683168-25-003733 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 42 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250515 DATE AS OF CHANGE: 20250515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CNS Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001729427 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 822318545 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39126 FILM NUMBER: 25955087 BUSINESS ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 BUSINESS PHONE: 1-800-946-9185 MAIL ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 10-Q 1 cns_i10q-033125.htm FORM 10-Q FOR MAR 2025 CNS Pharmaceuticals, Inc. 10-Q false --12-31 2025 Q1 0001729427 0001729427 2025-01-01 2025-03-31 0001729427 2025-05-15 0001729427 2025-03-31 0001729427 2024-12-31 0001729427 2024-01-01 2024-03-31 0001729427 us-gaap:CommonStockMember 2024-12-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001729427 us-gaap:RetainedEarningsMember 2024-12-31 0001729427 us-gaap:CommonStockMember 2023-12-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001729427 us-gaap:RetainedEarningsMember 2023-12-31 0001729427 2023-12-31 0001729427 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001729427 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001729427 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001729427 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001729427 us-gaap:CommonStockMember 2025-03-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001729427 us-gaap:RetainedEarningsMember 2025-03-31 0001729427 us-gaap:CommonStockMember 2024-03-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001729427 us-gaap:RetainedEarningsMember 2024-03-31 0001729427 2024-03-31 0001729427 2024-06-03 2024-06-04 0001729427 2025-02-20 2025-02-21 0001729427 us-gaap:WarrantMember 2025-01-01 2025-03-31 0001729427 CNSP:UnvestedRestrictedStockUnitsMember 2025-01-01 2025-03-31 0001729427 CNSP:UnvestedPerformanceUnitsMember 2025-01-01 2025-03-31 0001729427 CNSP:OptionsMember 2025-01-01 2025-03-31 0001729427 us-gaap:WarrantMember 2024-01-01 2024-03-31 0001729427 CNSP:UnvestedRestrictedStockUnitsMember 2024-01-01 2024-03-31 0001729427 CNSP:UnvestedPerformanceUnitsMember 2024-01-01 2024-03-31 0001729427 CNSP:OptionsMember 2024-01-01 2024-03-31 0001729427 CNSP:November2023NoteMember 2023-11-28 0001729427 CNSP:November2023NoteMember 2023-11-27 2023-11-28 0001729427 CNSP:November2023NoteMember 2025-03-31 0001729427 us-gaap:CommonStockMember 2024-05-01 0001729427 us-gaap:CommonStockMember 2025-03-31 0001729427 2024-05-01 0001729427 CNSP:AGPATMSalesAgreementMember 2025-01-01 2025-03-31 0001729427 CNSP:AGPATMSalesAgreement1Member 2025-01-01 2025-03-31 0001729427 CNSP:Plan2017Member 2017-12-31 0001729427 CNSP:Plan2020Member 2020-12-31 0001729427 CNSP:Plan2020Member 2023-08-08 2024-08-09 0001729427 us-gaap:StockOptionMember 2025-01-01 2025-03-31 0001729427 us-gaap:StockOptionMember 2024-01-01 2024-03-31 0001729427 us-gaap:StockOptionMember 2025-03-31 0001729427 CNSP:Plan2017Member 2025-03-31 0001729427 CNSP:Plan2020Member 2025-03-31 0001729427 CNSP:WarrantsMember 2025-01-01 2025-03-31 0001729427 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-03-31 0001729427 us-gaap:RestrictedStockUnitsRSUMember 2025-03-31 0001729427 CNSP:PerformanceUnitsMember 2025-01-01 2025-03-31 0001729427 CNSP:PerformanceUnitsMember 2025-03-31 0001729427 CNSP:StockOptionsMember 2024-12-31 0001729427 CNSP:StockOptionsMember 2025-01-01 2025-03-31 0001729427 CNSP:StockOptionsMembe